Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

British Journal of Cancer

Volumn 90, Issue 4, 2004, Pages 906-910

  Ching, L M ^a   Zwain, S ^a   Baguley, B C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antivascular; Apoptosis; Blood flow; Hoechst 33342; Knockout mice; Tumour necrosis factor

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; HOE 33342; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULAR TARGETING AGENT; 5,6 DIMETHYLXANTHENONEACETIC ACID; 5,6-DIMETHYLXANTHENONEACETIC ACID; ANTINEOPLASTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN; BREAST CARCINOMA; COLON TUMOR; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; GENE DISRUPTION; HEART; HISTOCHEMISTRY; KNOCKOUT MOUSE; LIVER; MAXIMUM TOLERATED DOSE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TISSUE SPECIFICITY; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; WILD TYPE; ANIMAL; ANIMAL DISEASE; BIOSYNTHESIS; BLOOD FLOW; EXPERIMENTAL NEOPLASM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; IN SITU NICK-END LABELING; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; REGIONAL BLOOD FLOW; TUMOR NECROSIS FACTOR-ALPHA; XANTHONES;

EID: 1642352048     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601606     Document Type: Article

References (13)

1. Baguley BC (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4: 141-148
2. Ching L-M, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86: 1937-1942
3. Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC (1999) Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethybcanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59: 3304-3307
4. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P (2003) Phase I trial of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Br J Cancer 88: 1844-1850
5. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR (1998) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78: 439-445
6. Philpott M, Baguley BC, Ching L-M (1995) Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36: 143-148
7. Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217-222
8. Rustin G, Galbraith S, Taylor N, Stratford M, Bradley C, Thompson P, Jameson M, Baguley B (1998) Impact on tumour perfusion measured by dynamic magnetic resonance imaging (MRI), in the phase 1 trial of 5,6- dimethylxanthenone-4-acetic acid (DMXAA). Ann Oncol 9: 126
9. Watts ME, Woodcock M (1992) Flavone acetic acid induced changes in human endothelial permeability - potentiation by tumour-conditioned medium. Eur J Cancer 28A: 1628-1632
10. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77: 1-10
11. Zhao L, Ching LM, Kestell P, Baguley BC (2002) The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. Br J Cancer 87: 465-470
12. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1989) Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J Natl Cancer Inst 81: 1005-1013
13. Zwi LJ, Baguley BC, Gavin JB, Wilson WR (1994) Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6: 79-85